End Brexit uncertainty for at-risk UK pharma sector, says cross-party committee

17 May 2018
ukparliament-big

The prospect of leaving the European Union (EU) without an agreement that protects the UK’s pharmaceutical industry would be disastrous for just about everyone with a stake in the sector – from drugmakers to patients.

That is the stark conclusion of a report published on Thursday by the Business, Energy and Industrial Strategy (BEIS) Committee in its latest analysis on the effect the UK’s withdrawal from the EU will have on a sector of the economy.

"The government’s own analysis identifies pharmaceuticals as the sector for which UK/EU market access is the most important given the industry is reliant on friction-free border movement for their products"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical